Decadron Phosphate, Ophthalmic Side Effects

Generic name: dexamethasone ophthalmic

Medically reviewed by Drugs.com. Last updated on Jun 1, 2024.

Note: This document provides detailed information about Decadron Phosphate, Ophthalmic.

Applies to dexamethasone ophthalmic: intraocular implant, intraocular suspension, ophthalmic insert, ophthalmic ointment, ophthalmic solution, ophthalmic suspension Side Effects associated with dexamethasone ophthalmic. Some dosage forms listed on this page may not apply specifically to the brand name Decadron Phosphate, Ophthalmic.

Applies to dexamethasone ophthalmic: intraocular implant, intraocular suspension, ophthalmic insert, ophthalmic ointment, ophthalmic solution, ophthalmic suspension.

General

The most commonly reported side effects were cataract, elevation of intraocular pressure, and conjunctival hemorrhage.^[Ref]

Ocular

• Very common (10% or more): Cataract (up to 68%), elevation of intraocular pressure (28%), conjunctival hemorrhage (22%)
• Common (1% to 10%): Eye pain, conjunctival hyperemia, ocular hypertension, reduced visual acuity, conjunctivitis, vitreous floaters, conjunctival edema, dry eye, vitreous detachment, vitreous opacities, retinal aneurysm, foreign body sensation, corneal erosion, keratitis, anterior chamber inflammation, retinal tear, eyelid ptosis, vitreous detachment, keratoconjunctivitis sicca, corneal staining, photophobia, blurred vision, eye pruritus, increased lacrimation
• Rare (less than 0.1%): Burning, stinging
• Frequency not reported: Glaucoma with optic nerve damage, visual acuity and visual field defects, subcapsular cataract formation, secondary ocular infection and perforation of the globe

Postmarketing experience: Complication of device insertion (implant misplacement), device dislocation with or without corneal edema, endophthalmitis, hypotony of the eye (associated with vitreous leakage due to injection), retinal detachment^[Ref]

Cardiovascular

• Very common (10% or more): Hypertension (13%)^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Uncommon (0.1% to 1%): Dysgeusia, migraine
• Frequency not reported: Dizziness^[Ref]

Respiratory

• Common (1% to 10%): Bronchitis^[Ref]

Endocrine

• Postmarketing reports: Cushing's syndrome, adrenal suppression

Cushing's syndrome and adrenal suppression may occur at doses higher than recommended in predisposed patients including children and those on CYP P450 3A4 inhibitors.

Further information

Decadron Phosphate, Ophthalmic side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer